

FEMSelect Investors,

We are pleased to share with you the attached **Press Release that will go public on the wires tomorrow, Tuesday, May 4th announcing FEMSelect and LiNA Medical USA (LiNA) entering a Strategic Sales Partnership.**

The Sales Promotion Pilot between FEMSelect and LiNA Medical USA over the past few months has been successful in solidifying the interest of both parties to move to the next step. We have worked out the details and are now launching a Strategic Sales Partnership which includes:

- Investment by LiNA in Physician Professional Education program as per FEMSelect's design
- Investment by LiNA in additional direct sales representatives
- LiNA assumption of physician professional marketing
- Exclusive Distribution of EnPlace through LiNA in the US as of July 1, 2021

Conversations continue with investors regarding a \$5M Round B which will enable FEMSelect to finalize Transfer to Mass Production, Quality Management System, clinical trial data/publications and consumer marketing. Relationships and conversations with other Strategics continue in the background to plan toward Exit.

We will be hosting a FEMSelect investor call on Monday, May 24th 8amEST to discuss this opportunity with you as well as the EnPlace 1-Year Clinical data further. Please let us know if you would like to join the Zoom call.

Thanks,
Debbie